Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection
Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.
The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.
This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.
Bio-Techne (NASDAQ: TECH) ha annunciato una partnership strategica con Spear Bio per la distribuzione di immunoassay ultrasensibili di nuova generazione dedicati alla ricerca sulle malattie neurodegenerative. Questa collaborazione segue la partecipazione di Bio-Techne al finanziamento Series A da 45 milioni di dollari di Spear Bio nel 2024.
La collaborazione si concentrerà sulla distribuzione della tecnologia piattaforma SPEAR di Spear Bio, che garantisce una sensibilità superiore di 2-3 ordini di grandezza rispetto alle piattaforme immunoassay attuali. L'offerta iniziale è focalizzata sui principali biomarcatori dell'Alzheimer, tra cui pTau 217, GFAP, Nf-L e pTau 231.
Questa partnership sfrutta la rete di distribuzione globale e l'expertise in immunoassay di Bio-Techne insieme alla tecnologia ultrasensibile di Spear Bio per promuovere la diagnosi precoce delle malattie e lo sviluppo di terapie.
Bio-Techne (NASDAQ: TECH) ha anunciado una asociación estratégica con Spear Bio para distribuir inmunoensayos ultrasensibles de próxima generación para la investigación de enfermedades neurodegenerativas. La asociación se produce tras la participación de Bio-Techne en la ronda de financiación Serie A de 45 millones de dólares de Spear Bio en 2024.
La colaboración se centrará en distribuir la tecnología de plataforma SPEAR de Spear Bio, que ofrece una sensibilidad 2-3 órdenes de magnitud superior a las plataformas de inmunoensayo actuales. La oferta inicial se dirige a biomarcadores clave de la enfermedad de Alzheimer, incluyendo pTau 217, GFAP, Nf-L y pTau 231.
Esta asociación aprovecha la red global de distribución y la experiencia en inmunoensayos de Bio-Techne junto con la tecnología ultrasensible de Spear Bio para avanzar en la detección temprana de enfermedades y el desarrollo terapéutico.
Bio-Techne (NASDAQ: TECH)는 Spear Bio와 전략적 파트너십을 체결하여 신경퇴행성 질환 연구를 위한 차세대 초감도 면역측정법을 배포한다고 발표했습니다. 이번 파트너십은 2024년 Spear Bio의 4,500만 달러 규모 시리즈 A 투자에 Bio-Techne가 참여한 데 따른 것입니다.
이번 협력은 Spear Bio의 SPEAR 플랫폼 기술 배포에 중점을 두며, 이는 기존 면역측정 플랫폼보다 2~3단계 높은 감도를 제공합니다. 초기 제품은 pTau 217, GFAP, Nf-L, pTau 231 등 알츠하이머병 주요 바이오마커를 대상으로 합니다.
이번 파트너십은 Bio-Techne의 글로벌 유통망과 면역측정 전문성에 Spear Bio의 초감도 기술을 결합하여 조기 질병 진단과 치료 개발을 촉진합니다.
Bio-Techne (NASDAQ : TECH) a annoncé un partenariat stratégique avec Spear Bio pour distribuer des immunoessais ultrasensibles de nouvelle génération dédiés à la recherche sur les maladies neurodégénératives. Ce partenariat fait suite à la participation de Bio-Techne au financement de série A de 45 millions de dollars de Spear Bio en 2024.
La collaboration portera sur la distribution de la technologie de plateforme SPEAR de Spear Bio, offrant une sensibilité 2 à 3 ordres de grandeur supérieure aux plateformes d'immunoessais actuelles. L'offre initiale cible les principaux biomarqueurs de la maladie d'Alzheimer, notamment pTau 217, GFAP, Nf-L et pTau 231.
Ce partenariat combine le réseau mondial de distribution et l'expertise en immunoessais de Bio-Techne avec la technologie ultrasensible de Spear Bio afin de faire progresser la détection précoce des maladies et le développement thérapeutique.
Bio-Techne (NASDAQ: TECH) hat eine strategische Partnerschaft mit Spear Bio angekündigt, um ultrasensitive Immunoassays der nächsten Generation für die Forschung an neurodegenerativen Erkrankungen zu vertreiben. Die Partnerschaft folgt auf die Beteiligung von Bio-Techne an der 45 Millionen US-Dollar Series A Finanzierung von Spear Bio im Jahr 2024.
Der Fokus der Zusammenarbeit liegt auf dem Vertrieb der SPEAR Plattformtechnologie von Spear Bio, die eine 2-3 Größenordnungen höhere Sensitivität als aktuelle Immunoassay-Plattformen bietet. Das erste Angebot richtet sich auf wichtige Alzheimer-Biomarker wie pTau 217, GFAP, Nf-L und pTau 231.
Diese Partnerschaft nutzt das globale Vertriebsnetz und die Immunoassay-Expertise von Bio-Techne zusammen mit der ultrasensitiven Technologie von Spear Bio, um die Früherkennung von Krankheiten und die Entwicklung von Therapien voranzutreiben.
- Partnership enables detection of biomarkers with 100-1000x higher sensitivity than current platforms
- Expands Bio-Techne's presence in high-growth neurodegenerative disease markets
- Strategic investment through participation in Spear Bio's $45M Series A funding
- Leverages Bio-Techne's global distribution network for market expansion
- None.
Insights
Bio-Techne's partnership with Spear Bio strengthens its position in the high-growth neurodegenerative biomarker market with superior detection technology.
This strategic partnership between Bio-Techne and Spear Bio represents a significant technological advancement in the biomarker detection landscape. Spear Bio's SPEAR platform delivers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms – a dramatic improvement that could fundamentally change how neurodegenerative diseases are researched and eventually diagnosed.
The initial focus on Alzheimer's biomarkers is strategically sound. The ability to detect key markers like pTau 217, GFAP, Nf-L, and pTau 231 with unprecedented sensitivity addresses a critical unmet need in neurodegenerative research. This positions Bio-Techne to capture value in the growing market for precision neurology tools.
Bio-Techne's previous participation in Spear Bio's
The technology's relevance beyond neurology to inflammation and oncology suggests substantial market expansion potential. For Bio-Techne investors, this partnership represents both immediate revenue opportunities through distribution and longer-term strategic value as biomarker-driven approaches gain further traction in therapeutic development and clinical practice.
Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms, developing early interventions, and advancing clinical trials. Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms.
"Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research" said Will Geist, President of Bio-Techne's Protein Sciences Segment. "By leveraging Bio-Techne's global reach and immunoassay expertise with Spear Bio's ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity."
With Bio-Techne's global reach, Spear Bio is well-positioned to accelerate the deployment of its next-generation assay technology, enabling researchers to detect biomarkers in historically challenging conditions. Spear Bio's initial focus is neurodegenerative diseases, with the technology relevant for inflammation, oncology and additional fields. In addition, Spear Bio's advanced detection technology expands applications in high-growth markets, including early neurodegenerative disease diagnosis, enhancing patient access to critical interventions.
"Our strategic partnership with Bio-Techne represents a transformative opportunity for neurodegenerative disease research," said Feng Xuan, PhD, Founder and CEO of Spear Bio. "By combining Bio-Techne's global distribution network and market leadership with Spear Bio's next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders."
This partnership underscores the promise of Spear Bio's SPEAR technology and reinforces Bio-Techne's commitment to advancing biomarker detection.
Learn more about Spear Bio and Bio-Techne
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Spear Bio
Founded in 2021 and headquartered in
To learn more about the company, please visit https://spear.bio/biomarker-research-applications/spear-ultradetect-assays/.
Bio-Techne Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
Spear Bio Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-spear-bio-announce-strategic-partnership-to-advance-therapeutic-development-with-ultrasensitive-biomarker-detection-302504480.html
SOURCE Bio-Techne Corporation
FAQ
What is the partnership between Bio-Techne (NASDAQ: TECH) and Spear Bio?
How much more sensitive is Spear Bio's SPEAR platform compared to current technologies?
What was Bio-Techne's investment in Spear Bio?
Which disease areas will the Bio-Techne and Spear Bio partnership initially focus on?
How will the Bio-Techne partnership help Spear Bio's market reach?
